The clinical motivation behind the work is rooted in a long-recognized paradox. Clinicians have known for decades that traumatic brain injury accelerates bone healing and can even induce heterotopic ossification, the abnormal formation of bone in soft tissues. Patients with severe fractures alongside brain injuries often heal their skeletons at remarkable speed. This observation suggested that the injured brain sends signals that enhance bone repair, a phenomenon explored in earlier studies showing that the damaged brain releases small extracellular vesicles that target osteoprogenitor cells. But the reverse question — whether bone, in turn, can benefit the injured brain — had remained largely unexplored. The new study set out to answer it directly, asking whether the skeleton’s endocrine function could be deliberately harnessed as a therapy for the brain.

To test this, the research team developed a protocol called dynamic compressive tibial axial loading, or DCTAL. In mice, the procedure involves applying rhythmic axial compression to the tibia — approximately 4 newtons of force at 2 hertz for 300 cycles per session, five times per week — a regimen that mimics the natural mechanical loads bones experience during vigorous walking or running without causing fractures or tissue damage. When mice subjected to moderate traumatic brain injury received this treatment, the results were striking: survival increased, motor performance on pole tests improved, and spatial memory assessed in the Morris water maze recovered substantially. The benefits extended beyond trauma, as mice subjected to ischemic stroke also showed better outcomes. The team then scaled the approach to a porcine model of traumatic brain injury, a clinically relevant large-animal system, and found that DCTAL similarly improved survival and reduced neuron loss in injured pigs.

Histological and molecular analysis of treated animals revealed the depth of the effect. DCTAL reduced brain lesion volume and preserved hippocampal neurons, as measured by MAP2 immunostaining and Nissl staining. Chronic neuroinflammation, one of the most damaging sequelae of traumatic brain injury, was markedly attenuated: the expression of pro-inflammatory cytokines including TNF-α, IL-1β and IL-6 declined, while anti-inflammatory mediators such as IL-4 and TGF-β rose. The proportions of inflammatory macrophages and neutrophils infiltrating the injured brain fell significantly. Significantly, the treatment also stimulated neuronal regeneration, consistent with elevated trophic support in the injured tissue.

The mechanistic heart of the study lies in osteocytes, the terminally differentiated bone cells that form a sensory network throughout the mineralized matrix. Osteocytes are well established as the primary mechanosensors of the skeleton, detecting fluid shear stress and strain through mechanosensitive ion channels. The researchers focused on PIEZO1, a pore-forming mechanosensitive channel previously shown to be required for bone formation. When the team genetically deleted Piezo1 specifically in osteocytes of mice, the protective effects of tibial compression vanished entirely — survival gains, motor and cognitive recovery, reduction of lesion volume and attenuation of inflammation all reversed. Conversely, locally activating PIEZO1 in bone, including with the channel agonist Yoda1 applied to cortical bone, was sufficient to reproduce the neuroprotective benefits without any loading at all. This established PIEZO1 in osteocytes as both necessary and sufficient for the phenomenon.

At the molecular level, the loading regimen transformed the osteocyte secretome. Transcriptomic profiling of tibial cortical bone revealed upregulation of secreted factors following DCTAL, and the researchers identified three key molecules released directly by osteocytes: IL-1R2, the decoy receptor for interleukin-1 that neutralizes inflammatory signaling; APOL11a, an apolipoprotein L family member; and HSP70, the inducible heat shock protein long associated with neuroprotection. In vitro, supernatant from Yoda1-treated cortical bone reduced caspase-3 cleavage and preserved MAP2 expression in neurons subjected to oxygen-glucose deprivation, an effect abolished when PIEZO1 was deleted from osteocytes. The AKT signaling pathway emerged as a mediator of mechanically induced HSP70 release from osteocyte-like MLO-Y4 cells, with the AKT inhibitor GSK690693 blocking HSP70 induction.

Beyond direct osteocyte secretions, the study found that loading also indirectly elevated circulating levels of BDNF, the canonical brain-derived neurotrophic factor; PF4, a platelet factor previously implicated in cognitive rejuvenation; and dopamine, the neuromodulator essential for motor control and cognitive function. When the researchers transferred serum from DCTAL-treated mice into mice with traumatic brain injury, the recipients recapitulated many of the therapeutic benefits, confirming that the recovery is driven by circulating humoral factors rather than local skeletal effects. The team further showed that these factors act synergistically — no single molecule fully accounted for the protection, suggesting a combinatorial endocrine program rather than a one-drug mechanism.

An important set of control experiments clarified the specificity of the effect. Tibial fracture, despite the well-known acceleration of bone healing after brain injury, failed to activate the protective osteokine program and did not improve cognitive or histological outcomes after traumatic brain injury. In fact, concomitant fracture elevated inflammatory cytokines and delayed recovery, consistent with clinical observations that fractures worsen brain injury outcomes. This distinction indicates that controlled dynamic loading, not skeletal damage, is the critical therapeutic variable. The study also assessed safety: bone mineral density of the tibia remained stable after weeks of loading, joint and meniscal structures showed no adverse changes, sciatic nerve histology was unremarkable, and healthy mice receiving DCTAL exhibited no motor or cognitive alterations, indicating that the intervention is well tolerated in uninjured animals.

The translational implications are considerable. Traumatic brain injury remains a leading cause of death and disability worldwide, and decades of clinical trials for neuroprotective drugs have largely failed, leaving rehabilitation and supportive care as the mainstays of treatment. A non-invasive or minimally invasive mechanical intervention that harnesses the body’s own skeletal endocrine machinery — activating a pathway that already exists in biology — could sidestep many of the delivery and toxicity problems that have plagued pharmacological approaches. The authors suggest that drug-based activation of osteocyte PIEZO1, or of downstream osteokine pathways, might eventually reproduce the benefits of mechanical loading in patients unable to undergo physical loading regimens. While substantial work remains before tibial compression or its pharmacological analogues reach human trials, including optimization of dosing parameters and validation of the factor cocktail in clinical settings, the demonstration that bone can be mechanically instructed to secrete brain-repairing signals fundamentally expands the view of the skeleton — from a structural scaffold to a programmable endocrine organ with direct influence over the injured brain.

Subject of Research: Mechanically activated osteocyte PIEZO1 signaling in a bone–brain axis that promotes recovery after traumatic brain injury and stroke

Article Title: Tibial bone compression promotes recovery after brain injury through osteocyte PIEZO1

Article References: Tibial bone compression promotes recovery after brain injury through osteocyte PIEZO1. (n.d.). https://doi.org/10.1038/s41593-026-02422-w

Image Credits: AI Generated

DOI: 10.1038/s41593-026-02422-w

Keywords: bone-brain axis, osteocytes, PIEZO1, traumatic brain injury, stroke, tibial loading, osteokines, HSP70, IL-1R2, APOL11a, BDNF, neuroprotection

The clinical backdrop to the work is well established. Epidemiological studies have repeatedly shown that patients with Parkinson’s disease face a strikingly elevated risk of osteoporosis and osteoporotic fractures, a burden that exceeds what can be explained by poor mobility, falls, or age alone. Meta-analyses cited by the researchers indicate high rates of osteoporotic fracture in Parkinson’s disease, and cross-sectional clinical work has associated biomarkers such as serum uric acid with reduced bone mineral density in affected patients. Yet the molecular mechanisms that bind neurodegeneration to bone loss have remained murky. The Henan University team set out to interrogate that relationship experimentally, asking whether a single genetic factor—absence of ACE2—could simultaneously perturb dopaminergic neuron survival in the brain and bone homeostasis in the skeleton.

To do so, the researchers used a well-characterized mouse model of parkinsonism in which the neurotoxin MPTP, or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, selectively destroys dopamine-producing neurons in the substantia nigra. Crucially, they crossed this challenge with mice lacking a functional ACE2 gene—specifically Ace2-null males, designated Ace2−/y—because ACE2 sits at the center of the protective arm of the renin-angiotensin system, converting angiotensin II into angiotensin-(1–7), a peptide with documented anti-inflammatory and neuroprotective actions. Previous studies from other groups and from the same team had shown that ACE2 activation mitigates behavioral deficits and neuroinflammation in chemically induced Parkinson’s models, and that the ACE2/Ang-(1–7)/Mas cascade strengthens bone structure and metabolism. The new study asked what happens when this protective factor is removed entirely under parkinsonian stress.

Behavioral testing revealed a clear aggravating effect. MPTP exposure significantly worsened motor dysfunction and depression-like behaviors in the mice, and the combination of MPTP toxicity with ACE2 deficiency produced a particularly severe pathological picture in the brain. Immunohistochemistry, Western blotting, and histopathological staining showed reduced activity of dopaminergic neurons and heightened microglial activation—the inflammatory response of the brain’s resident immune cells. At the molecular level, the researchers measured elevated levels of total α-synuclein, the misfolding-prone protein that defines Parkinson’s pathology, alongside increased abundance of Caspase-3 and Bax, two canonical executioners of programmed cell death. Together, these markers indicate that ACE2 loss intensifies both the protein aggregation burden and the apoptotic pressure on vulnerable neurons.

The bone findings were equally striking, and notably they emerged in parallel rather than secondarily. In the skeletal tissue of the Ace2-deficient mice, the team documented reduced abundance of total Wnt ligands, β-catenin, bone morphogenetic proteins (BMP), and insulin-like growth factor 1 (IGF-1), along with diminished phosphorylation ratios of the downstream kinases that transmit these signals. This matters because each of these cascades is a cornerstone of bone formation: Wnt/β-catenin signaling drives osteoblast differentiation and bone accrual, BMPs are potent inducers of bone formation used clinically in spine fusion and fracture repair, and IGF-1 couples muscle and bone metabolism through mTOR-dependent pathways. The researchers are careful to note that the parallel reduction of these signaling proteins suggests potential perturbation of the cascades rather than definitive proof of pathway failure, a distinction that reflects appropriate scientific caution.

In the opposite direction, ACE2 deficiency upregulated mediators of the RANKL/RANK/OPG axis, a triad that governs osteoclast formation and bone resorption. RANKL binding to RANK on osteoclast precursors drives the differentiation of bone-resorbing cells, while OPG acts as a soluble decoy receptor that restrains the process. Dysregulation of this axis tilts bone turnover toward net loss. Intriguingly, the same axis operates in the brain, where it has been identified as a critical inflammatory signaling system in ischemic injury, and Rho GTPases downstream of these pathways modulate osteoclast differentiation directly. The coordinated shift of this inflammatory skeletal axis in both brain and bone tissue under ACE2 deficiency is one of the study’s most suggestive observations, hinting at a common pathological language spoken by the two organs.

To move from candidate pathways to gene-level targets, the team turned to transcriptomics. They mined public GEO datasets and applied weighted gene co-expression network analysis, or WGCNA, a computational method that groups genes into modules based on correlated expression patterns and identifies the hub genes most central to disease-associated modules. This analysis pinpointed ten hub genes, including DNM1, which encodes dynamin 1, a protein essential for synaptic vesicle recycling; OCRL, a phosphatidylinositol phosphate phosphatase linked to the oculocerebrorenal syndrome; and OPA1, a mitochondrial fusion protein whose mutations cause dominant optic atrophy and which has been implicated in mitochondrial parkinsonism through stem cell modeling. The dysregulation of these genes was linked to synaptic dysfunction and inflammation—two processes squarely at the heart of Parkinson’s pathophysiology.

The team then evaluated whether these hub genes could serve as diagnostic biomarkers. Using receiver operating characteristic, or ROC, analysis on public single-disease transcriptome datasets for Parkinson’s disease and osteoporosis separately, they found that the core gene signatures achieved areas under the curve ranging from 0.683 to 0.981, indicating diagnostic accuracy that spans moderate to near-perfect discrimination. Functional enrichment of the core genes pointed to involvement in synaptic signaling, MAPK signaling, and the Rap1 and Ras pathways—small GTPase cascades that regulate cell proliferation, differentiation, and cytoskeletal dynamics in both neurons and bone cells. Such dual-diagnostic performance, if replicated in human cohorts, would suggest that a shared molecular signature underlies both conditions and could be exploited clinically to identify patients at risk of combined neurodegenerative and skeletal decline.

The authors are appropriately measured in their claims. They emphasize that these are preclinical findings obtained under short-term MPTP treatment in growing young male mice, meaning that the observed bone metabolic disturbance was transient and that the results may not translate directly to elderly human patients, in whom Parkinson’s disease typically manifests and in whom bone loss is chronic and sex-dependent. They also stress that the coordinated dysregulation observed in brain and bone is consistent with a bone-brain axis pathological phenotype, but that the current experimental design cannot confirm causal bidirectional cross-talk between the tissues. Distinguishing whether ACE2 deficiency independently damages both organs, or whether pathology in one propagates to the other—perhaps through circulating osteocalcin, sympathetic nervous system output, or inflammatory mediators—will require interventional studies that manipulate one tissue and measure the other.

Even with those caveats, the study offers a compelling framework and a set of concrete targets for follow-up. Restoring ACE2 activity or mimicking its product, angiotensin-(1–7), has already shown neuroprotective effects in experimental Parkinson’s models, including reduced α-synuclein expression through the NEAT1/miR-153-3p axis, and ACE2 activation has been reported to promote hippocampal neurogenesis via Wnt/β-catenin signaling. The present results raise the possibility that such therapies could carry a skeletal benefit as well, protecting against the osteoporosis that so often compounds the disability of Parkinson’s disease. The ten hub genes, meanwhile, provide a molecular shortlist for mechanistic validation, and their diagnostic AUC values justify testing in human blood or tissue datasets. As the bone-brain axis matures from a descriptive concept into a mechanistic research program, work like this demonstrates how a single molecule, studied across two organs at once, can illuminate disease connections that medicine has long observed clinically but struggled to explain at the level of genes and signaling pathways.

Subject of Research: ACE2-dependent molecular mechanisms linking Parkinson's disease neurodegeneration and bone metabolic alterations via the bone-brain axis

Article Title: ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis

Article References: Liu, T., Ren, Y., Tian, X., & Wei, J. (2026). ACE2 and Parkinsonism‑related bone metabolic alterations: signaling pathways and hub gene analysis. Molecular Genetics and Genomics, 301(1), Article 185. https://doi.org/10.1007/s00438-026-02511-2

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02511-2

Keywords: Parkinson's disease, ACE2, bone metabolism, bone-brain axis, osteoporosis, Wnt/beta-catenin signaling, RANKL/RANK/OPG, IGF-1, hub genes, WGCNA, alpha-synuclein, MPTP mouse model